57歲李姓男子是B型肝炎帶原者，被檢出肝臟中央有顆11公分的腫瘤，且已轉移至肝臟左葉，平均存活期只剩10多個月，幸好兒子捐出肝臟移植，讓李男重獲生機。
成大醫院移植外科醫師林毅志今天指出，李男未接受定期追蹤檢查，結果在一次健康檢查中被檢出肝臟中央有顆11公分的腫瘤，且已轉移到肝臟左葉，確診是肝癌中期。依臨床案例統計，肝癌中期平均存活期只有10多個月，5年存活率僅約2成。
醫師考量腫瘤分布和肝功能，排除手術切除的可能性，李男最後接受肝動脈化學栓塞術，成功縮小腫瘤，達到可進行肝臟移植的標準，即將步入婚姻的兒子也願意捐贈肝臟；李男肝臟移植手術十分成功，也能續享天倫之樂。
林毅志表示，肝癌好發於有病理變化的肝臟，慢性肝炎及肝硬化患者是發生肝癌的危險族群；肝臟已有病理變化的病人，可接受積極手術切除的不多，即使接受治療，已有慢性肝炎或肝硬化的剩餘肝臟，仍是發生肝癌的危險環境。
因此，治療肝癌的策略雖很多，但復發機率也很高，手術切除後的病人5年復發率高達5成至7成，更不用說治療成效較差的病患。
林毅志說，近年來，移植醫學已累積很多經驗，確立可移植肝癌患者的腫瘤期別標準，讓移植肝臟作為治療肝癌的策略之一，成效也經由實證醫學的證實。
The 57-year-old man named Li was born with hepatitis B. He was found to have a tumor of 11 cm in the center of the liver and had metastasized to the left lobe of the liver. The average survival period was only over 10 months. Fortunately, the son donated the liver transplant. Let Li Nan regain his vitality.
Lin Yizhi, a transplant surgeon at Chengda Hospital, pointed out today that Li Nan did not receive regular follow-up examinations. The results showed that a tumor of 11 cm in the center of the liver was detected in a health check and had been transferred to the left lobe of the liver. The diagnosis was mid-stage of liver cancer. According to clinical statistics, the average survival time of liver cancer is only 10 months, and the 5-year survival rate is only about 20%.
Physicians considered tumor distribution and liver function, and ruled out the possibility of surgical resection. Li Nan finally accepted hepatic arterial chemoembolization, successfully reduced the tumor, and reached the standard for liver transplantation. The son who is about to enter the marriage is also willing to donate the liver; Li Nan Liver transplant surgery is very successful, and you can continue to enjoy your family.
Lin Yizhi said that liver cancer occurs in livers with pathological changes. Patients with chronic hepatitis and cirrhosis are at risk of developing liver cancer. Patients with pathological changes in the liver can receive less active surgical resection, even if they receive treatment. The remaining liver of chronic hepatitis or cirrhosis is still a dangerous environment for liver cancer.
Therefore, although there are many strategies for treating liver cancer, the chance of recurrence is also high. The 5-year recurrence rate of patients after surgical resection is as high as 50% to 70%, not to mention patients with poor treatment.
Lin Yizhi said that in recent years, transplant medicine has accumulated a lot of experience, established the tumor stage standard for transplantable liver cancer patients, and made the transplanted liver as one of the strategies for treating liver cancer, and the effect was also confirmed by empirical medicine.
laennec is the ethical drug manufactured with JBP’s unique technologies.
Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standards.
留言列表
